Soltis Investment Advisors LLC Purchases 461 Shares of Bristol-Myers Squibb (NYSE:BMY)

Soltis Investment Advisors LLC lifted its stake in Bristol-Myers Squibb (NYSE:BMY) by 6.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,843 shares of the biopharmaceutical company’s stock after purchasing an additional 461 shares during the quarter. Soltis Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $444,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in BMY. AMF Tjanstepension AB boosted its position in shares of Bristol-Myers Squibb by 6.9% in the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock worth $31,618,000 after purchasing an additional 39,419 shares in the last quarter. Ritholtz Wealth Management boosted its position in shares of Bristol-Myers Squibb by 81.0% in the 3rd quarter. Ritholtz Wealth Management now owns 23,843 shares of the biopharmaceutical company’s stock worth $1,234,000 after purchasing an additional 10,669 shares in the last quarter. Exchange Traded Concepts LLC boosted its position in shares of Bristol-Myers Squibb by 18.1% in the 3rd quarter. Exchange Traded Concepts LLC now owns 26,468 shares of the biopharmaceutical company’s stock worth $1,369,000 after purchasing an additional 4,064 shares in the last quarter. Koshinski Asset Management Inc. boosted its position in shares of Bristol-Myers Squibb by 3.5% in the 3rd quarter. Koshinski Asset Management Inc. now owns 26,568 shares of the biopharmaceutical company’s stock worth $1,375,000 after purchasing an additional 904 shares in the last quarter. Finally, Sound Income Strategies LLC raised its holdings in Bristol-Myers Squibb by 46.9% in the 3rd quarter. Sound Income Strategies LLC now owns 2,770 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 885 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on BMY shares. Citigroup boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and boosted their target price for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research note on Friday. BMO Capital Markets boosted their target price on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research note on Tuesday, November 12th. Finally, Sanford C. Bernstein started coverage on shares of Bristol-Myers Squibb in a research note on Thursday, October 17th. They set a “market perform” rating and a $56.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $57.86.

Bristol-Myers Squibb Price Performance

NYSE:BMY opened at $55.50 on Tuesday. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The business’s 50-day simple moving average is $57.56 and its two-hundred day simple moving average is $53.89. The stock has a market cap of $112.55 billion, a PE ratio of -12.56, a P/E/G ratio of 2.13 and a beta of 0.45. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.81% and a negative net margin of 18.53%. As a group, analysts forecast that Bristol-Myers Squibb will post 6.75 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, January 3rd. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a yield of 4.47%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.